-
1
-
-
77954254610
-
-
National Osteoporosis Foundation Washington. DC: National Osteoporosis Foundation
-
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington. DC: National Osteoporosis Foundation. 2010.
-
(2010)
Clinician's Guide to Prevention and Treatment of Osteoporosis
-
-
-
2
-
-
0036001310
-
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
-
Vahle JL, Masahiko S, Long GG, Young JK, Francis PC, Englehardt JA, Westmore MS, Ma YL, Nold JB., Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30: 312.
-
(2002)
Toxicol Pathol.
, vol.30
, pp. 312
-
-
Vahle, J.L.1
Masahiko, S.2
Long, G.G.3
Young, J.K.4
Francis, P.C.5
Englehardt, J.A.6
Westmore, M.S.7
Ma, Y.L.8
Nold, J.B.9
-
3
-
-
33845769891
-
Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84. in a 2-year study in Fischer 344 rats
-
Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS., Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84. in a 2-year study in Fischer 344 rats. Toxicol Pathol. 2006; 34 (7): 929-40.
-
(2006)
Toxicol Pathol.
, vol.34
, Issue.7
, pp. 929-940
-
-
Jolette, J.1
Wilker, C.E.2
Smith, S.Y.3
Doyle, N.4
Hardisty, J.F.5
Metcalfe, A.J.6
Marriott, T.B.7
Fox, J.8
Wells, D.S.9
-
4
-
-
69149106680
-
T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling
-
Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, Gilbert L, Nanes MS, Zayzafoon M, Guldberg R, Lamar DL, Singer MA, Lane TF, Kronenberg HM, Weitzmann MN, Pacifici R., T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009; 10 (3): 229-40.
-
(2009)
Cell Metab.
, vol.10
, Issue.3
, pp. 229-240
-
-
Terauchi, M.1
Li, J.Y.2
Bedi, B.3
Baek, K.H.4
Tawfeek, H.5
Galley, S.6
Gilbert, L.7
Nanes, M.S.8
Zayzafoon, M.9
Guldberg, R.10
Lamar, D.L.11
Singer, M.A.12
Lane, T.F.13
Kronenberg, H.M.14
Weitzmann, M.N.15
Pacifici, R.16
-
5
-
-
26844521277
-
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
-
Bellido T, Ali AA, Gubrij I, Potkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL., Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146 (11): 4577-83.
-
(2005)
Endocrinology.
, vol.146
, Issue.11
, pp. 4577-4583
-
-
Bellido, T.1
Ali, A.A.2
Gubrij, I.3
Potkin, L.I.4
Fu, Q.5
O'Brien, C.A.6
Manolagas, S.C.7
Jilka, R.L.8
-
6
-
-
0037591085
-
The cellular and clinical parameters of anabolic therapy for osteoporosis
-
Rosen CJ., The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gen Expr. 2003; 13 (1): 25-38.
-
(2003)
Crit Rev Eukaryot Gen Expr.
, vol.13
, Issue.1
, pp. 25-38
-
-
Rosen, C.J.1
-
7
-
-
17144383676
-
Identifying genes that regulate bone remodeling as potential therapeutic targets
-
Krane SM., Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med. 2005; 201 (6): 841-3.
-
(2005)
J Exp Med.
, vol.201
, Issue.6
, pp. 841-843
-
-
Krane, S.M.1
-
8
-
-
3242667700
-
Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone. (1-34)
-
Buxton EC, Yao W, Lane NE., Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone. (1-34). J Clin Endocrinol Metab. 2004; 89 (7): 3332-6.
-
(2004)
J Clin Endocrinol Metab.
, vol.89
, Issue.7
, pp. 3332-3336
-
-
Buxton, E.C.1
Yao, W.2
Lane, N.E.3
-
9
-
-
44849121708
-
Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window
-
Bilezikian JP., Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008; 6 (1): 24-38.
-
(2008)
Curr Osteoporos Rep.
, vol.6
, Issue.1
, pp. 24-38
-
-
Bilezikian, J.P.1
-
10
-
-
0026657511
-
Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone
-
Bradbeer JN, Arlot ME, Meunier PJ, Reeve J., Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol. 1992; 37: 282-9.
-
(1992)
Clin Endocrinol.
, vol.37
, pp. 282-289
-
-
Bradbeer, J.N.1
Arlot, M.E.2
Meunier, P.J.3
Reeve, J.4
-
11
-
-
0033926149
-
Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis
-
Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH., Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone. 2000; 27 (2): 311-8.
-
(2000)
Bone.
, vol.27
, Issue.2
, pp. 311-318
-
-
Hodsman, A.B.1
Kisiel, M.2
Adachi, J.D.3
Fraher, L.J.4
Watson, P.H.5
-
12
-
-
57449090596
-
Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone. 1-84
-
Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA., Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone. 1-84. Bone. 2009; 44: 13-9.
-
(2009)
Bone.
, vol.44
, pp. 13-19
-
-
Recker, R.R.1
Bare, S.P.2
Smith, S.Y.3
Varela, A.4
Miller, M.A.5
Morris, S.A.6
-
13
-
-
0025753221
-
Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients
-
Hodsman AB, Steer BM, Fraher LJ, Drost DJ., Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 1991; 14: 67-83.
-
(1991)
Bone Miner.
, vol.14
, pp. 67-83
-
-
Hodsman, A.B.1
Steer, B.M.2
Fraher, L.J.3
Drost, D.J.4
-
14
-
-
0026167127
-
HPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses
-
Reeve J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP., hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporos Int. 1991; 1: 162-70.
-
(1991)
Osteoporos Int.
, vol.1
, pp. 162-170
-
-
Reeve, J.1
Bradbeer, J.N.2
Arlot, M.3
Davies, U.M.4
Green, J.R.5
Hampton, L.6
Edouard, C.7
Hesp, R.8
Hulme, P.9
Ashby, J.P.10
-
15
-
-
0022758151
-
Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
-
Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, Neer RM., Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res. 1986; 1: 377-81.
-
(1986)
J Bone Miner Res.
, vol.1
, pp. 377-381
-
-
Slovik, D.M.1
Rosenthal, D.I.2
Doppelt, S.H.3
Potts, Jr.J.T.4
Daly, M.A.5
Campbell, J.A.6
Neer, R.M.7
-
16
-
-
0034812187
-
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study
-
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, PlavetiA K, Müller R, Bilezikian JP, Lindsay R., Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16: 846-53.
-
(2001)
J Bone Miner Res.
, vol.16
, pp. 846-853
-
-
Dempster, D.W.1
Cosman, F.2
Kurland, E.S.3
Zhou, H.4
Nieves, J.5
Woelfert, L.6
Shane, E.7
Plavetia, K.8
Müller, R.9
Bilezikian, J.P.10
Lindsay, R.11
-
17
-
-
0242413030
-
Recombinant human parathyroid hormone (1-34) (teriparatide) improves both cortical and cancellous bone structure
-
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF., Recombinant human parathyroid hormone (1-34) (teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932-41.
-
(2003)
J Bone Miner Res.
, vol.18
, pp. 1932-1941
-
-
Jiang, Y.1
Zhao, J.J.2
Mitlak, B.H.3
Wang, O.4
Genant, H.K.5
Eriksen, E.F.6
-
18
-
-
0002651961
-
Assessment of effects of ly333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital x-ray radiogrammetry
-
Hyldstrup L, Jorgensen JT, Gaich G., Assessment of effects of ly333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital x-ray radiogrammetry. Bone. 2002; 28: S97.
-
(2002)
Bone.
, vol.28
-
-
Hyldstrup, L.1
Jorgensen, J.T.2
Gaich, G.3
-
19
-
-
4243224802
-
Teriparatide [rhPTH(1-34)] improves the structural geometry of the hip
-
Uusi-Rasi K, Beck TJ, Oreskovic TL, Sato M, Bogado CE, Zanchetta JR., Teriparatide [rhPTH(1-34)] improves the structural geometry of the hip. J Bone Miner Res. 2002; 17: S208.
-
(2002)
J Bone Miner Res.
, vol.17
-
-
Uusi-Rasi, K.1
Beck, T.J.2
Oreskovic, T.L.3
Sato, M.4
Bogado, C.E.5
Zanchetta, J.R.6
-
20
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
-
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 (19): 1434 -.
-
(2001)
N Engl J Med.
, vol.344
, Issue.19
, pp. 1434
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
Prince, R.4
Gaich, G.A.5
Reginster, J.Y.6
Hodsman, A.B.7
Eriksen, E.F.8
Ish-Shalom, S.9
Genant, H.K.10
Wang, O.11
Mitlak, B.H.12
-
21
-
-
84856108386
-
Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: Meta-analysis of randomised controlled trials
-
Han SL, Wan SL., Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012; 66 (2): 199-209.
-
(2012)
Int J Clin Pract.
, vol.66
, Issue.2
, pp. 199-209
-
-
Han, S.L.1
Wan, S.L.2
-
22
-
-
84864937214
-
Comparative effectiveness of drug treatments to prevent fragility fractures: A systematic review and network meta-analysis
-
Jun
-
Murad MH, Drake MT, Mullan RJ, Mauch KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM., Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012 Jun; 97 (6): 1871-80.
-
(2012)
J Clin Endocrinol Metab.
, vol.97
, Issue.6
, pp. 1871-1880
-
-
Murad, M.H.1
Drake, M.T.2
Mullan, R.J.3
Mauch, K.F.4
Stuart, L.M.5
Lane, M.A.6
Abu Elnour, N.O.7
Erwin, P.J.8
Hazem, A.9
Puhan, M.A.10
Li, T.11
Montori, V.M.12
-
23
-
-
84877948489
-
Treatment to prevent fractures in men and women with low bone density or osteoporosis: Update of a 2007 report [Internet]
-
AHRQ Publication No. 12-EHC023-EF Prepared by Southern California Evidence-based Practice Center-RAND Corporation, Santa Monica, CA, under Contract No. HHSA-290-2007-1006 2-I. Rockville, MD: Agency for Healthcare Research and Quality; 2012 Mar [cited 2012 Oct 18]
-
Crandall CC, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG., Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report [Internet]. Comparative Effectiveness Review No. 53. AHRQ Publication No. 12-EHC023-EF Prepared by Southern California Evidence-based Practice Center-RAND Corporation, Santa Monica, CA, under Contract No. HHSA-290-2007-1006 2-I. Rockville, MD: Agency for Healthcare Research and Quality; 2012 Mar [cited 2012 Oct 18]. Available from. http:// effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction= displayproduct&productid=1006.
-
Comparative Effectiveness Review No. 53
-
-
Crandall, C.C.1
Newberry, S.J.2
Gellad, W.G.3
Diamant, A.4
Lim, Y.W.5
Suttorp, M.6
Motala, A.7
Ewing, B.8
Roth, B.9
Timmer, M.10
Shanman, R.11
Shekelle, P.G.12
-
24
-
-
0033550968
-
Mortality after all major types of osteoporotic fracture in men and women: An observational study
-
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA., Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353 (9156): 878-82.
-
(1999)
Lancet.
, vol.353
, Issue.9156
, pp. 878-882
-
-
Center, J.R.1
Nguyen, T.V.2
Schneider, D.3
Sambrook, P.N.4
Eisman, J.A.5
-
25
-
-
0033710488
-
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
-
Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP., Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endrocrinol Metab. 2000; 85 (9): 3069-76.
-
(2000)
J Clin Endrocrinol Metab.
, vol.85
, Issue.9
, pp. 3069-3076
-
-
Kurland, E.S.1
Cosman, F.2
McMahon, D.J.3
Rosen, C.J.4
Lindsay, R.5
Bilezikian, J.P.6
-
26
-
-
0037214255
-
The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis
-
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA., The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18 (1): 9-17.
-
(2003)
J Bone Miner Res.
, vol.18
, Issue.1
, pp. 9-17
-
-
Orwoll, E.S.1
Scheele, W.H.2
Paul, S.3
Adami, S.4
Syversen, U.5
Diez-Perez, A.6
Kaufman, J.M.7
Clancy, A.D.8
Gaich, G.A.9
-
27
-
-
22844447275
-
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy
-
Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH., Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporosis Int. 2005; 16 (5): 510-6.
-
(2005)
Osteoporosis Int.
, vol.16
, Issue.5
, pp. 510-516
-
-
Kaufman, J.M.1
Orwoll, E.2
Goemaere, S.3
San Martin, J.4
Hossain, A.5
Dalsky, G.P.6
Lindsay, R.7
Mitlak, B.H.8
-
28
-
-
36148958951
-
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
-
Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R., Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357 (20): 2028-39.
-
(2007)
N Engl J Med.
, vol.357
, Issue.20
, pp. 2028-2039
-
-
Saag, K.G.1
Shane, E.2
Boonen, S.3
Marin, F.4
Donley, D.W.5
Taylor, K.A.6
Dalsky, G.P.7
Marcus, R.8
-
29
-
-
70350555320
-
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial
-
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR., Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60 (11): 3346-55.
-
(2009)
Arthritis Rheum.
, vol.60
, Issue.11
, pp. 3346-3355
-
-
Saag, K.G.1
Zanchetta, J.R.2
Devogelaer, J.P.3
Adler, R.A.4
Eastell, R.5
See, K.6
Krege, J.H.7
Krohn, K.8
Warner, M.R.9
-
30
-
-
0345305666
-
Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis
-
Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R., Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003; 88 (11): 5212-20.
-
(2003)
J Clin Endocrinol Metab.
, vol.88
, Issue.11
, pp. 5212-5220
-
-
Hodsman, A.B.1
Hanley, D.A.2
Ettinger, M.P.3
Bolognese, M.A.4
Fox, J.5
Metcalfe, A.J.6
Lindsay, R.7
-
31
-
-
33947504500
-
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis
-
Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB., Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med. 2007; 146: 326-39.
-
(2007)
Ann Intern Med.
, vol.146
, pp. 326-339
-
-
Greenspan, S.L.1
Bone, H.G.2
Ettinger, M.P.3
Hanley, D.A.4
Lindsay, R.5
Zanchetta, J.R.6
Blosch, C.M.7
Mathisen, A.L.8
Morris, S.A.9
Marriott, T.B.10
-
32
-
-
77958131700
-
Treatment of postmenopausal women with osteoporosis with PTH (1-84) for 36 months: Treatment extension study
-
Zanchetta JR, Bogado CE, Cisari C, Aslanidis S, Greisen H, Fox J, Lems W., Treatment of postmenopausal women with osteoporosis with PTH (1-84) for 36 months: treatment extension study. Curr Med Res Opin. 2010; 26 (11): 2627-33.
-
(2010)
Curr Med Res Opin.
, vol.26
, Issue.11
, pp. 2627-2633
-
-
Zanchetta, J.R.1
Bogado, C.E.2
Cisari, C.3
Aslanidis, S.4
Greisen, H.5
Fox, J.6
Lems, W.7
-
33
-
-
15944389876
-
Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures
-
Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH., Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005; 90 (3): 1583-7.
-
(2005)
J Clin Endocrinol Metab.
, vol.90
, Issue.3
, pp. 1583-1587
-
-
Gallagher, J.C.1
Genant, H.K.2
Crans, G.G.3
Vargas, S.J.4
Krege, J.H.5
-
34
-
-
23744447531
-
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
-
McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley D, Dalsky GP, Eriksen EF., Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165 (15): 1762-8.
-
(2005)
Arch Intern Med.
, vol.165
, Issue.15
, pp. 1762-1768
-
-
McClung, M.R.1
San Martin, J.2
Miller, P.D.3
Civitelli, R.4
Bandeira, F.5
Omizo, M.6
Donley, D.7
Dalsky, G.P.8
Eriksen, E.F.9
-
35
-
-
33846447882
-
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
-
Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH., Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21 (11): 1785-90.
-
(2006)
J Bone Miner Res.
, vol.21
, Issue.11
, pp. 1785-1790
-
-
Chen, P.1
Miller, P.D.2
Delmas, P.D.3
Misurski, D.A.4
Krege, J.H.5
-
36
-
-
84861181435
-
New understanding and treatments for osteoporosis
-
Mazziotti G, Bilezikian JP, Canalis E, Cocchi D, Giustina A., New understanding and treatments for osteoporosis. Endocrine. 2012; 41: 58-69.
-
(2012)
Endocrine.
, vol.41
, pp. 58-69
-
-
Mazziotti, G.1
Bilezikian, J.P.2
Canalis, E.3
Cocchi, D.4
Giustina, A.5
-
37
-
-
0029798867
-
Synthetic human parathyroid hormone 1-34. vs calcitriol,calcium in the treatment of hypoparathyroidism
-
Winer KK, Yanovski JA, Cutler GB Jr., Synthetic human parathyroid hormone 1-34. vs calcitriol,calcium in the treatment of hypoparathyroidism. JAMA. 1996; 276: 631-6.
-
(1996)
JAMA
, vol.276
, pp. 631-636
-
-
Winer, K.K.1
Yanovski, J.A.2
Cutler, Jr.G.B.3
-
38
-
-
0031773242
-
Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone. 1-34 in treatment of hypoparathyroidism
-
Winer KK, Yanovski JA, Sarani B., Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone. 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998; 83: 3480-6.
-
(1998)
J Clin Endocrinol Metab.
, vol.83
, pp. 3480-3486
-
-
Winer, K.K.1
Yanovski, J.A.2
Sarani, B.3
-
39
-
-
0141564588
-
Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone (1-34) versus calcitriol and calcium
-
Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr., Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone (1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003; 88: 4214-20.
-
(2003)
J Clin Endocrinol Metab.
, vol.88
, pp. 4214-4220
-
-
Winer, K.K.1
Ko, C.W.2
Reynolds, J.C.3
Dowdy, K.4
Keil, M.5
Peterson, D.6
Gerber, L.H.7
McGarvey, C.8
Cutler, Jr.G.B.9
-
40
-
-
84863029403
-
Synthetic human parathyroid hormone. 1-34. replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism
-
Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS., Cutler GB Jr., Synthetic human parathyroid hormone. 1-34. replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97 (2): 391-9.
-
(2012)
J Clin Endocrinol Metab.
, vol.97
, Issue.2
, pp. 391-399
-
-
Winer, K.K.1
Zhang, B.2
Shrader, J.A.3
Peterson, D.4
Smith, M.5
Albert, P.S.6
Cutler, Jr.G.B.7
-
41
-
-
80053185721
-
The effect of adding PTH (1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study
-
Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L., and the hypoparathyroid study group. The effect of adding PTH (1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011; 26: 2358-70.
-
(2011)
J Bone Miner Res.
, vol.26
, pp. 2358-2370
-
-
Sikjaer, T.1
Rejnmark, L.2
Rolighed, L.3
Heickendorff, L.4
Mosekilde, L.5
-
42
-
-
78149409817
-
Therapy of hypoparathyroidism with intact parathyroid hormone
-
Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP., Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010; 21: 1927-34.
-
(2010)
Osteoporos Int.
, vol.21
, pp. 1927-1934
-
-
Rubin, M.R.1
Sliney, Jr.J.2
McMahon, D.J.3
Silverberg, S.J.4
Bilezikian, J.P.5
-
43
-
-
80054976969
-
PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism
-
Rubin MR, Dempster DW, Sliney J Jr, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP., PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011; 26: 2727-36.
-
(2011)
J Bone Miner Res.
, vol.26
, pp. 2727-2736
-
-
Rubin, M.R.1
Dempster, D.W.2
Sliney, Jr.J.3
Zhou, H.4
Nickolas, T.L.5
Stein, E.M.6
Dworakowski, E.7
Dellabadia, M.8
Ives, R.9
McMahon, D.J.10
Zhang, C.11
Silverberg, S.J.12
Shane, E.13
Cremers, S.14
Bilezikian, J.P.15
-
44
-
-
84869433403
-
-
June 23-26, Houston, TX
-
Bilezikian JP, Mosekilde L, Shoback D, Vokes T, Mannstadt M, Clarke B, Lagast H, Garceau R., Efficacy of recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of adults with hypoparathyroidism: a randomized, double-blind, placebo-controlled study. Presented at The 94th Annual Meeting of The Endocrine Society;. 2012 June 23-26, Houston, TX.
-
(2012)
Efficacy of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults with Hypoparathyroidism: A Randomized, Double-blind, Placebo-controlled Study. Presented at the 94th Annual Meeting of the Endocrine Society;.
-
-
Bilezikian, J.P.1
Mosekilde, L.2
Shoback, D.3
Vokes, T.4
Mannstadt, M.5
Clarke, B.6
Lagast, H.7
Garceau, R.8
-
45
-
-
84869389652
-
Effect of recombinant human parathyroid hormone (rhPTH[1-84]) on skeletal dynamics and BMD in hypoparathyroidism: The REPLACE study
-
October 11-26; Minneapolis, MN, USA
-
Bilezikian J, Clarke BL, Mannstadt M, Vokes TJ, Shoback D, Lagast H, Garceau R., Effect of recombinant human parathyroid hormone (rhPTH[1-84]) on skeletal dynamics and BMD in hypoparathyroidism: the REPLACE study. Presented at the ASBMR Annual Meeting;. 2012 October 11-26; Minneapolis, MN, USA.
-
(2012)
Presented at the ASBMR Annual Meeting;.
-
-
Bilezikian, J.1
Clarke, B.L.2
Mannstadt, M.3
Vokes, T.J.4
Shoback, D.5
Lagast, H.6
Garceau, R.7
-
46
-
-
84869459492
-
Treatment of hypoparathyroidism with PTH (1-84) is safe and effective for up to 4 years
-
September 16-20; San Diego, CA, USA
-
Cusano N, Rubin M, Ives R, Sliney J Jr, Bilezikian J., Treatment of hypoparathyroidism with PTH (1-84) is safe and effective for up to 4 years. Presented at the ASBMR Annual Meeting;. 2011 September 16-20; San Diego, CA, USA.
-
(2011)
Presented at the ASBMR Annual Meeting;.
-
-
Cusano, N.1
Rubin, M.2
Ives, R.3
Sliney, Jr.J.4
Bilezikian, J.5
-
47
-
-
84862662423
-
Mini-review: New therapeutic options in hypoparathyroidism
-
Cusano NE, Rubin MR, Sliney J Jr, Bilezikian JP., Mini-review: new therapeutic options in hypoparathyroidism. Endocrine. 2012; 41: 410-4.
-
(2012)
Endocrine.
, vol.41
, pp. 410-414
-
-
Cusano, N.E.1
Rubin, M.R.2
Sliney, Jr.J.3
Bilezikian, J.P.4
-
49
-
-
77953473271
-
Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
-
Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC., Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25 (2): 404-14.
-
(2010)
J Bone Miner Res.
, vol.25
, Issue.2
, pp. 404-414
-
-
Aspenberg, P.1
Genant, H.K.2
Johansson, T.3
Nino, A.J.4
See, K.5
Krohn, K.6
García-Hernández, P.A.7
Recknor, C.P.8
Einhorn, T.A.9
Dalsky, G.P.10
Mitlak, B.H.11
Fierlinger, A.12
Lakshmanan, M.C.13
-
50
-
-
80052871434
-
Parathyroid hormone. 1-84. accelerates fracture-healing in pubic bones of elderly osteoporotic women
-
Sep 7
-
Peichl P, Holzer LA, Maier R, Holzer G., Parathyroid hormone. 1-84. accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011 Sep 7; 93 (17): 1583-7.
-
(2011)
J Bone Joint Surg Am.
, vol.93
, Issue.17
, pp. 1583-1587
-
-
Peichl, P.1
Holzer, L.A.2
Maier, R.3
Holzer, G.4
-
51
-
-
84870782274
-
-
NIH ClinicalTrials gov identifier: NCT01473589 Bethesda, MD: NIH; 2012 [cited. 2012 Oct 18]
-
NIH ClinicalTrials gov identifier: NCT01473589. Effect of Teriparatide on Hip Fracture Healing [Internet]. Bethesda, MD: NIH; 2012 [cited. 2012 Oct 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT01473589.
-
Effect of Teriparatide on Hip Fracture Healing [Internet]
-
-
-
52
-
-
80052540017
-
Atypical femoral fractures during prolonged use of bisphosphonates: Short-term responses to strontium ranelate and teriparatide
-
Sep
-
Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F., Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011 Sep; 96 (9): 2675-80.
-
(2011)
J Clin Endocrinol Metab.
, vol.96
, Issue.9
, pp. 2675-2680
-
-
Carvalho, N.N.1
Voss, L.A.2
Almeida, M.O.3
Salgado, C.L.4
Bandeira, F.5
-
53
-
-
33847339685
-
Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]
-
Mar
-
Harper RP, Fung E., Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007 Mar; 65 (3): 573-80.
-
(2007)
J Oral Maxillofac Surg.
, vol.65
, Issue.3
, pp. 573-580
-
-
Harper, R.P.1
Fung, E.2
-
54
-
-
68849132188
-
Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy
-
Aug
-
Lau AN, Adachi JD., Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009 Aug; 36 (8): 1835-7.
-
(2009)
J Rheumatol.
, vol.36
, Issue.8
, pp. 1835-1837
-
-
Lau, A.N.1
Adachi, J.D.2
-
55
-
-
3242887547
-
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
-
Jul-Aug
-
Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M., Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004 Jul-Aug; 32 (4): 426-38.
-
(2004)
Toxicol Pathol.
, vol.32
, Issue.4
, pp. 426-438
-
-
Vahle, J.L.1
Long, G.G.2
Sandusky, G.3
Westmore, M.4
Ma, Y.L.5
Sato, M.6
-
56
-
-
44449104186
-
Perspective on the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PT. H(1-84)
-
Jun
-
Tashjian AH, Goltzman D., Perspective on the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PT. H(1-84). J Bone Miner Res. 2008 Jun; 23 (6): 803-10.
-
(2008)
J Bone Miner Res.
, vol.23
, Issue.6
, pp. 803-810
-
-
Tashjian, A.H.1
Goltzman, D.2
-
57
-
-
66149135224
-
International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons
-
Jul
-
Mirabello L, Troisi RJ, Savage SA., International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009 Jul; 125 (1): 229-34.
-
(2009)
Int J Cancer.
, vol.125
, Issue.1
, pp. 229-234
-
-
Mirabello, L.1
Troisi, R.J.2
Savage, S.A.3
-
58
-
-
79955086282
-
Using epidemiology and genomics to understand osteosarcoma etiology
-
Savage SA, Mirabello L., Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011; 2011: 548151.
-
(2011)
Sarcoma.
, vol.2011
, pp. 548151
-
-
Savage, S.A.1
Mirabello, L.2
-
59
-
-
63449118087
-
Osteosarcoma incidence and survival rates from. 1973 to 2004: Data from the Surveillance
-
Apr
-
Mirabello L, Troisi RJ, Savage SA., Osteosarcoma incidence and survival rates from. 1973 to 2004: data from the Surveillance. Epidemiology, and End Results Program. Cancer. 2009; Apr; 115 (7): 1531-43.
-
(2009)
Epidemiology, and End Results Program. Cancer.
, vol.115
, Issue.7
, pp. 1531-1543
-
-
Mirabello, L.1
Troisi, R.J.2
Savage, S.A.3
-
60
-
-
84870796024
-
-
U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Rockville, MD: Center for Drug Evaluation and Research 2000 May 19 [cited. 2012 Oct 18]
-
U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Development of parathyroid hormone for the prevention and treatment of osteoporosis. Draft guidance. Rockville, MD: Center for Drug Evaluation and Research 2000 May 19 [cited. 2012 Oct 18]. Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071618.pdf.
-
Guidance for Industry. Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis. Draft Guidance
-
-
-
61
-
-
84863087584
-
Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34))
-
Watanabe A, Yoneyama S, Nakajima M, Sato N, Takao-Kawabata R, Isogai Y, Sakurai-Tanikawa A, Higuchi K, Shimoi A, Yamatoya H, Yoshida K, Kohira T., Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). J Toxicol Sci. 2012; 37 (3): 617-29.
-
(2012)
J Toxicol Sci.
, vol.37
, Issue.3
, pp. 617-629
-
-
Watanabe, A.1
Yoneyama, S.2
Nakajima, M.3
Sato, N.4
Takao-Kawabata, R.5
Isogai, Y.6
Sakurai-Tanikawa, A.7
Higuchi, K.8
Shimoi, A.9
Yamatoya, H.10
Yoshida, K.11
Kohira, T.12
-
62
-
-
0035137942
-
Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)
-
Feb
-
Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R., Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 2001 Feb; 28 (2): 150-9.
-
(2001)
Bone.
, vol.28
, Issue.2
, pp. 150-159
-
-
Jerome, C.P.1
Burr, D.B.2
Van Bibber, T.3
Hock, J.M.4
Brommage, R.5
-
63
-
-
0032865052
-
Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis)
-
Sep
-
Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L., Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 1999 Sep; 25 (3): 301-9.
-
(1999)
Bone.
, vol.25
, Issue.3
, pp. 301-309
-
-
Jerome, C.P.1
Johnson, C.S.2
Vafai, H.T.3
Kaplan, K.C.4
Bailey, J.5
Capwell, B.6
Fraser, F.7
Hansen, L.8
Ramsay, H.9
Shadoan, M.10
Lees, C.J.11
Thomsen, J.S.12
Mosekilde, L.13
-
64
-
-
56749181173
-
Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]
-
Dec
-
Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M., Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res. 2008 Dec; 23 (12): 2033-9.
-
(2008)
J Bone Miner Res.
, vol.23
, Issue.12
, pp. 2033-2039
-
-
Vahle, J.L.1
Zuehlke, U.2
Schmidt, A.3
Westmore, M.4
Chen, P.5
Sato, M.6
-
65
-
-
0035697651
-
The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys
-
Majumdar S. Bay B.K. editors. New York: Plenum; pp
-
Turner CH, Burr DB, Hock JM, Brommage R, Sato M., The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. In:, Majumdar S, Bay BK, editors Non-invasive assessment of trabecular bone architecture and the competence of bone. New York: Plenum; pp 165-180. 2001.
-
(2001)
Non-invasive Assessment of Trabecular Bone Architecture and the Competence of Bone
, pp. 165-180
-
-
Turner, C.H.1
Burr, D.B.2
Hock, J.M.3
Brommage, R.4
Sato, M.5
-
66
-
-
33846477811
-
Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine
-
Feb
-
Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY., Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res. 2007 Feb; 22 (2): 260-73.
-
(2007)
J Bone Miner Res.
, vol.22
, Issue.2
, pp. 260-273
-
-
Fox, J.1
Miller, M.A.2
Newman, M.K.3
Turner, C.H.4
Recker, R.R.5
Smith, S.Y.6
-
67
-
-
84869413759
-
The US Postmarketing Surveillance Study of Adult Osteosarcoma Teriparatide study design findings from the first 7 years
-
Andrews E, Gilsenan A, Midkiff K, Sherril B, Wu Y, Mann B, Masica D., The US Postmarketing Surveillance Study of Adult Osteosarcoma Teriparatide study design findings from the first 7 years. JBMR. 2012 27.
-
(2012)
JBMR
, vol.27
-
-
Andrews, E.1
Gilsenan, A.2
Midkiff, K.3
Sherril, B.4
Wu, Y.5
Mann, B.6
Masica, D.7
-
68
-
-
33846543133
-
Osteosarcoma and teriparatide?
-
Feb
-
Harper KD, Krege JH, Marcus R, Mitlak BH., Osteosarcoma and teriparatide?. J Bone Miner Res. 2007 Feb; 22 (2): 334.
-
(2007)
J Bone Miner Res.
, vol.22
, Issue.2
, pp. 334
-
-
Harper, K.D.1
Krege, J.H.2
Marcus, R.3
Mitlak, B.H.4
-
69
-
-
77954553687
-
Of mice and men: Divergent risks of teriparatide-induced osteosarcoma
-
Jun
-
Subbiah V, Madsen VSS, Raymond AK, Benjamin RS, Ludwig JA., Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010 Jun; 21 (6): 1041-5.
-
(2010)
Osteoporos Int.
, vol.21
, Issue.6
, pp. 1041-1045
-
-
Subbiah, V.1
Madsen, V.S.S.2
Raymond, A.K.3
Benjamin, R.S.4
Ludwig, J.A.5
-
70
-
-
84869432427
-
Case report: Osteosarcoma and teriparatide (abstract). Poster presented at the ASBMR 31st Annual Meeting
-
24)
-
Lubitz R, Prasad S., Case report: osteosarcoma and teriparatide (abstract). Poster presented at the ASBMR 31st Annual Meeting. J Bone Miner Res. 2009; 24 (Suppl 1): SU0354.
-
(2009)
J Bone Miner Res.
, Issue.SUPPL. 1
-
-
Lubitz, R.1
Prasad, S.2
-
71
-
-
77953438185
-
Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH(1-84) in the treatment of postmenopausal osteoporosis
-
Pietrogrande L., Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH(1-84) in the treatment of postmenopausal osteoporosis. Int J Womens Health. 2009; 1: 193-203.
-
(2009)
Int J Womens Health.
, vol.1
, pp. 193-203
-
-
Pietrogrande, L.1
-
72
-
-
0035991225
-
Commentary on clinical safety of recombinant human parathyroid hormone. 1-34 in the treatment of osteoporosis in men and postmenopausal women
-
Jul
-
Tashjian AH Jr, Chabner BA., Commentary on clinical safety of recombinant human parathyroid hormone. 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res. 2002 Jul; 17 (7): 1151-61.
-
(2002)
J Bone Miner Res.
, vol.17
, Issue.7
, pp. 1151-1161
-
-
Tashjian, Jr.A.H.1
Chabner, B.A.2
-
73
-
-
24144465673
-
Primary hyperparathyroidism and osteosarcoma; Examination of a large cohort identifies three cases of fibroblastic osteosarcoma
-
Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF., Primary hyperparathyroidism and osteosarcoma; examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res. 2005; 20: 1562-8.
-
(2005)
J Bone Miner Res.
, vol.20
, pp. 1562-1568
-
-
Jimenez, C.1
Yang, Y.2
Kim, H.W.3
Al-Sagier, F.4
Berry, D.A.5
El-Naggar, A.K.6
Patel, S.7
Vassilopoulou-Sellin, R.8
Gagel, R.F.9
-
74
-
-
84933876926
-
On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol
-
Selye H., On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology. 1932; 16: 547-58.
-
(1932)
Endocrinology.
, vol.16
, pp. 547-558
-
-
Selye, H.1
-
75
-
-
21344454577
-
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
-
Aug
-
Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK., Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005 Aug; 26 (5): 688-703.
-
(2005)
Endocr Rev.
, vol.26
, Issue.5
, pp. 688-703
-
-
Hodsman, A.B.1
Bauer, D.C.2
Dempster, D.W.3
Dian, L.4
Hanley, D.A.5
Harris, S.T.6
Kendler, D.L.7
McClung, M.R.8
Miller, P.D.9
Olszynski, W.P.10
Orwoll, E.11
Yuen, C.K.12
-
76
-
-
0032005049
-
Survival after the diagnosis of hyperparathyroidism: A population-based study
-
Feb
-
Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM, Melton LJ 3rd., Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med. 1998 Feb; 104 (2): 115-22.
-
(1998)
Am J Med.
, vol.104
, Issue.2
, pp. 115-122
-
-
Wermers, R.A.1
Khosla, S.2
Atkinson, E.J.3
Grant, C.S.4
Hodgson, S.F.5
O'Fallon, W.M.6
Melton III, L.J.7
-
77
-
-
78649328893
-
Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis
-
Dec
-
Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H., Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010 Dec; 87 (6): 485-92.
-
(2010)
Calcif Tissue Int.
, vol.87
, Issue.6
, pp. 485-492
-
-
Satterwhite, J.1
Heathman, M.2
Miller, P.D.3
Marín, F.4
Glass, E.V.5
Dobnig, H.6
-
78
-
-
0030897225
-
Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers
-
Mar
-
Schwietert HR, Groen EW, Sollie FA, Jonkman JH., Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther. 1997 Mar; 61 (3): 360-6.
-
(1997)
Clin Pharmacol Ther.
, vol.61
, Issue.3
, pp. 360-366
-
-
Schwietert, H.R.1
Groen, E.W.2
Sollie, F.A.3
Jonkman, J.H.4
-
79
-
-
0141796739
-
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
-
Sep
-
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM., The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep; 349 (13): 1216-26.
-
(2003)
N Engl J Med.
, vol.349
, Issue.13
, pp. 1216-1226
-
-
Finkelstein, J.S.1
Hayes, A.2
Hunzelman, J.L.3
Wyland, J.J.4
Lee, H.5
Neer, R.M.6
-
80
-
-
77951644239
-
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis
-
Apr
-
Finkelstein JS, Wyland JJ, Lee H, Neer RM., Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr; 95 (4): 1838-45.
-
(2010)
J Clin Endocrinol Metab.
, vol.95
, Issue.4
, pp. 1838-1845
-
-
Finkelstein, J.S.1
Wyland, J.J.2
Lee, H.3
Neer, R.M.4
-
81
-
-
33845370793
-
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
-
Jan
-
Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH., Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007 Jan; 18 (1): 59-68.
-
(2007)
Osteoporos Int.
, vol.18
, Issue.1
, pp. 59-68
-
-
Miller, P.D.1
Schwartz, E.N.2
Chen, P.3
Misurski, D.A.4
Krege, J.H.5
-
82
-
-
34548762125
-
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
-
Sep
-
Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R., Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab. 2007 Sep; 92 (9): 3535-41.
-
(2007)
J Clin Endocrinol Metab.
, vol.92
, Issue.9
, pp. 3535-3541
-
-
Miller, P.D.1
Bilezikian, J.P.2
Diaz-Curiel, M.3
Chen, P.4
Marin, F.5
Krege, J.H.6
Wong, M.7
Marcus, R.8
-
83
-
-
33646237343
-
Initial experience with teriparatide in the United States
-
Apr
-
Gold DT, Pantos BS, Masica DN, Misurski DA, Marcus R., Initial experience with teriparatide in the United States. Curr Med Res Opin. 2006 Apr; 22 (4): 703-8.
-
(2006)
Curr Med Res Opin.
, vol.22
, Issue.4
, pp. 703-708
-
-
Gold, D.T.1
Pantos, B.S.2
Masica, D.N.3
Misurski, D.A.4
Marcus, R.5
-
84
-
-
0141684971
-
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
-
Sep 25
-
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ., PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25; 349 (13): 1207-15.
-
(2003)
N Engl J Med.
, vol.349
, Issue.13
, pp. 1207-1215
-
-
Black, D.M.1
Greenspan, S.L.2
Ensrud, K.E.3
Palermo, L.4
McGowan, J.A.5
Lang, T.F.6
Garnero, P.7
Bouxsein, M.L.8
Bilezikian, J.P.9
Rosen, C.J.10
-
85
-
-
65949115286
-
PTH (1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation
-
Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, Roschger P, Klaushofer K, Winer KK., PTH (1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res. 2009; 24: 964-73.
-
(2009)
J Bone Miner Res.
, vol.24
, pp. 964-973
-
-
Theman, T.A.1
Collins, M.T.2
Dempster, D.W.3
Zhou, H.4
Reynolds, J.C.5
Brahim, J.S.6
Roschger, P.7
Klaushofer, K.8
Winer, K.K.9
-
86
-
-
36849048891
-
Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study
-
Adachi JD, Hanley DA, Lorraine JK, Yu M., Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther. 2007; 29: 2055-69.
-
(2007)
Clin Ther.
, vol.29
, pp. 2055-2069
-
-
Adachi, J.D.1
Hanley, D.A.2
Lorraine, J.K.3
Yu, M.4
-
87
-
-
67349206106
-
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
-
Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH., Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int. 2009; 20: 943-8.
-
(2009)
Osteoporos Int.
, vol.20
, pp. 943-948
-
-
Lindsay, R.1
Miller, P.2
Pohl, G.3
Glass, E.V.4
Chen, P.5
Krege, J.H.6
-
88
-
-
72449146207
-
Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)
-
Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljnggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F., Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int. 2009; 85: 484-93.
-
(2009)
Calcif Tissue Int.
, vol.85
, pp. 484-493
-
-
Langdahl, B.L.1
Rajzbaum, G.2
Jakob, F.3
Karras, D.4
Ljnggren, O.5
Lems, W.F.6
Fahrleitner-Pammer, A.7
Walsh, J.B.8
Barker, C.9
Kutahov, A.10
Marin, F.11
-
89
-
-
51449096873
-
PTH (1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy
-
Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J., PTH (1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcif Tissue Int. 2008; 83: 85-92.
-
(2008)
Calcif Tissue Int.
, vol.83
, pp. 85-92
-
-
Fogelman, I.1
Fordham, J.N.2
Fraser, W.D.3
Spector, T.D.4
Christiansen, C.5
Morris, S.A.6
Fox, J.7
-
90
-
-
33749169801
-
Persistence with teriparatide in patients with osteoporosis: The UK experience
-
Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M., Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int. 2006; 17: 1626-9.
-
(2006)
Osteoporos Int.
, vol.17
, pp. 1626-1629
-
-
Arden, N.K.1
Earl, S.2
Fisher, D.J.3
Cooper, C.4
Carruthers, S.5
Goater, M.6
-
91
-
-
62149099988
-
Persistence with teriparatide in postmenopausal osteoporosis; Impact of a patient education and follow-up program: The French experience
-
Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C., Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009; 20: 625-30.
-
(2009)
Osteoporos Int.
, vol.20
, pp. 625-630
-
-
Briot, K.1
Ravaud, P.2
Dargent-Molina, P.3
Zylberman, M.4
Liu-Leage, S.5
Roux, C.6
-
92
-
-
84870843233
-
Improved adherence with PTH (1-84) for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis
-
Aug
-
Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA., Improved adherence with PTH (1-84) for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Osteoporosis Int. Epub. 2012 Aug 28.
-
(2012)
Osteoporosis Int. Epub.
, pp. 28
-
-
Black, D.M.1
Bilezikian, J.P.2
Greenspan, S.L.3
Wüster, C.4
Muñoz-Torres, M.5
Bone, H.G.6
Rosen, C.J.7
Andersen, H.S.8
Hanley, D.A.9
|